Head-to-head · Value Score
CoreAge Rx vs Layla
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Layla a 74. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameLayla
#157 · Grade C+ · Watch List
Est. first month
$297/mo month-to-month ($199/mo on a quarterly plan; $197 first month)
Save ~78% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 74 — an est. $99/mo first month, with no teaser step-up baked in. Layla isn't out of it: Someone who will read which of Layla's four plans they are on before the second charge lands.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Layla |
|---|---|---|
| Value Score | 93 (A+) | 74 (C+) |
| Est. first month | $99/mo | $297/mo month-to-month ($199/mo on a quarterly plan; $197 first month) |
| Save vs brand-name | ~89% | ~78% |
| Semaglutide | $99/mo | $297/mo month-to-month ($199/mo on a quarterly plan; $197 first month) |
| Tirzepatide | $149/mo | $399/mo month-to-month ($299/mo on a quarterly plan; $199 first month) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Layla
Layla sells compounded semaglutide and tirzepatide as injections or oral drops on monthly and quarterly plans, each opening with a discounted first month before stepping up to $297 and $399, or $199 and $299 on the quarterly terms.
Why it's a deal
- All four plans show the first-month price and the ongoing price side by side, so the step-up is visible before purchase rather than after
- Both molecules are offered as injections and as oral drops, and a brand-inclusive route exists for anyone who wants it
- Cancel any time is stated on every plan card
- Prescription, medication and shipping are described as included in each plan price
The fine print
- Every plan is a teaser: the first month is $99 to $199 and the ongoing rate is $199 to $399 depending which of the four you pick
- Layla's FAQ says GLP-1 medication "starts at $1299" while its plan cards start at $99, and nothing on the page reconciles the two
- The homepage was running a "Cyber Week is here" banner in late August, so its promotional messaging is not maintained
- The states Layla serves are not published, and its support line uses a UK number format
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Layla.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.